Pacira Pharmaceuticals, Inc. Reports Third Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
Wedbush Raises Price Target on Pacira Pharma (PCRX) Following 3Q Beat
October 27, 2015 5:20 PM EDTWedbush reiterated an Outperform rating on Pacira Pharmaceuticals (NASDAQ: PCRX), and raised the price target to $113.00 (from $106.00), following the company's 3Q earnings results. Total revenues of $62.2MM beat consensus of $60.4MM and diluted GAAP EPS of $0.08 also beat consensus of $0.02.
Analyst Liana Moussatos... More
Pacira Pharma (PCRX) Tops Q3 EPS by 20c
October 27, 2015 7:36 AM EDTPacira Pharma (NASDAQ: PCRX) reported Q3 EPS of $0.35, $0.20 better than the analyst estimate of $0.15. Revenue for the quarter came in at $62.2 million versus the consensus estimate of $60.44 million.
Pacira ended the third quarter of 2015 with cash and cash equivalents, short-term investments and long-term investments... More
